Kivu Bioscience Advances KIVU-305 to Phase 1 at World ADC London
25 Feb 2026 //
PHARMIWEB
Kivu Bio Appoints Julie Hambleton, M.D., To Board
27 Jan 2026 //
BUSINESSWIRE
Kivu Bioscience Doses First Patient in KIVU-107 Trial
12 Jan 2026 //
PHARMIWEB
Kivu Bioscience Names Sophia Randolph, M.D., Ph.D., CMO
27 Oct 2025 //
BUSINESSWIRE
Kivu Bioscience Shows Strong Anti-Tumor Activity Of KIVU-107
20 Oct 2025 //
PHARMIWEB
Kivu Bioscience Chooses Sterling Pharma for cGMP Manufacturing
02 Jun 2025 //
BUSINESSWIRE
Kivu Bioscience Raises $92M for Antibody-Drug Conjugates
28 Oct 2024 //
BUSINESSWIRE

Market Place
Sourcing Support